We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $5.98B
1-Year Est. Return 80.99%
This Fund
S&P 500
This Quarter Est. Return
+10.72%
1 Year Est. Return
+80.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$5.85B
AUM Growth
+$338M
Cap. Flow
+$79.4M
Cap. Flow %
1.36%
Top 10 Hldgs %
45.51%
Holding
707
New
76
Increased
198
Reduced
354
Closed
64

Top Buys

Rank Stock Value
1
TER icon
Teradyne
TER
+$60.1M
2
TSLA icon
Tesla
TSLA
+$32.1M
3
TSEM icon
Tower Semiconductor
TSEM
+$29.6M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$29M
5
PDD icon
Pinduoduo
PDD
+$28.1M

Top Sells

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$77.7M
2
BE icon
Bloom Energy
BE
+$53.1M
3
HOOD icon
Robinhood
HOOD
+$24.9M
4
SAP icon
SAP
SAP
+$24.1M
5
BIDU icon
Baidu
BIDU
+$21.5M

Sector Composition

Rank Sector Weight
1 Technology 51.21%
2 Communication Services 15.38%
3 Consumer Discretionary 13.01%
4 Healthcare 6.62%
5 Consumer Staples 4.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
351
Structure Therapeutics
GPCR
$3.52B
$91.3K ﹤0.01%
1,312
+34
+3% +$1.39K
ALKS icon
352
Alkermes
ALKS
$8.39B
$90.8K ﹤0.01%
3,244
-308
-9% -$9.22K
VNO icon
353
Vornado Realty Trust
VNO
$7.55B
$90K ﹤0.01%
2,705
+4
+0.1% +$146
ACAD icon
354
Acadia Pharmaceuticals
ACAD
$4.55B
$88.8K ﹤0.01%
3,324
-306
-8% -$7.31K
SRRK icon
355
Scholar Rock
SRRK
$5.87B
$88.3K ﹤0.01%
2,004
-64
-3% -$2.4K
INDV icon
356
Indivior Pharmaceuticals
INDV
$4.75B
$88K ﹤0.01%
2,453
-231
-9% -$7.05K
IMVT icon
357
Immunovant
IMVT
$8.11B
$87.5K ﹤0.01%
3,443
-307
-8% -$6.85K
KRG icon
358
Kite Realty
KRG
$5.88B
$87.3K ﹤0.01%
3,643
-56
-2% -$1.27K
CRNX icon
359
Crinetics Pharmaceuticals
CRNX
$8.85B
$86.8K ﹤0.01%
1,864
-162
-8% -$7.21K
FOLD
360
DELISTED
Amicus Therapeutics
FOLD
$86.3K ﹤0.01%
6,063
-569
-9% -$5.59K
DLTR icon
361
Dollar Tree
DLTR
$24.7B
$86.1K ﹤0.01%
700
– –
ADMA icon
362
ADMA Biologics
ADMA
$2.01B
$85.3K ﹤0.01%
4,676
-458
-9% -$7.72K
APGE icon
363
Apogee Therapeutics
APGE
$10.2B
$81.3K ﹤0.01%
1,077
+85
+9% +$5.35K
MIRM icon
364
Mirum Pharmaceuticals
MIRM
$6.87B
$79.6K ﹤0.01%
1,008
-73
-7% -$5.24K
NAMS icon
365
NewAmsterdam Pharma
NAMS
$3.33B
$78.2K ﹤0.01%
2,228
-195
-8% -$7.1K
AMRX icon
366
Amneal Pharmaceuticals
AMRX
$5.91B
$77.8K ﹤0.01%
6,178
-579
-9% -$6.63K
MAC icon
367
Macerich
MAC
$7.22B
$77.3K ﹤0.01%
4,188
+38
+0.9% +$670
MRSH
368
Marsh
MRSH
$91.4B
$77K ﹤0.01%
415
– –
SBRA icon
369
Sabra Healthcare REIT
SBRA
$5.38B
$75.2K ﹤0.01%
3,973
-20
-0.5% -$371
ACLX
370
DELISTED
Arcellx
ACLX
$74.1K ﹤0.01%
1,136
-57
-5% -$4.55K
PECO icon
371
Phillips Edison & Co
PECO
$5.45B
$74K ﹤0.01%
2,081
-4
-0.2% -$139
LGND icon
372
Ligand Pharmaceuticals
LGND
$5.94B
$73K ﹤0.01%
386
-36
-9% -$6.92K
CUZ icon
373
Cousins Properties
CUZ
$5.25B
$71.7K ﹤0.01%
2,783
-49
-2% -$1.27K
TERN
374
DELISTED
Terns Pharmaceuticals
TERN
$71.5K ﹤0.01%
1,770
-113
-6% -$2.61K
ARQT icon
375
Arcutis Biotherapeutics
ARQT
$3.5B
$69.9K ﹤0.01%
2,406
-174
-7% -$4.45K
13 14
15
16 17

Similar funds

CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
BP
BC Partners New York $5.96B AUM 15.21% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $5.94B AUM 18.44% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
AL
Appaloosa LP Short Hills, New Jersey $5.93B AUM 44.55% 1-Year Est. Return
CGPCS
Capital Group Private Client Services Los Angeles, California $5.93B AUM 27.73% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

GF Fund Management's Q4 2025 Portfolio in Review

As of Q4 2025, GF Fund Management held 707 positions worth $5.85B, up 6.1% from $5.51B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

GF Fund Management's Q4 2025 filing shows 76 new, 198 increased, 354 reduced and 64 closed positions. Its largest new stake was Teradyne: 350,137 shares worth $67.8M. The largest sale was Broadcom, an estimated $77.7M.

By sector, the portfolio is most concentrated in Technology at 51% of assets, up from 49% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q4 2025 buy was Teradyne: 350,137 shares worth $67.8M.
  • GF Fund Management added most to Tesla in Q4 2025, an estimated $32.1M increase.
  • GF Fund Management's biggest Q4 2025 reduction was Broadcom, cutting an estimated $77.7M.
  • GF Fund Management fully exited Baidu in Q4 2025, selling an estimated $21.5M.
  • GF Fund Management's ten largest holdings make up 46% of its $5.85B portfolio in Q4 2025.
  • GF Fund Management opened 76 new positions and closed 64 in Q4 2025.
  • GF Fund Management's portfolio value rose 6.1% quarter-over-quarter to $5.85B.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.